Galmed Pharmaceuticals
GLMD
10 hedge funds and large institutions have $38.3K invested in Galmed Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0.15% less ownership
Funds ownership: 0.52% → 0.37% (-0.15%)
17% less funds holding
Funds holding: 12 → 10 (-2)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
66% less capital invested
Capital invested by funds: $113K → $38.3K (-$74.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$22.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$755 |
| 3 |
AF
Allworth Financial
Folsom,
California
|
+$4 |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$4 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$83.1K |
| 2 |
Morgan Stanley
New York
|
-$12.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.33K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$2.84K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $36.1K | +$22.9K | +5,244 | +22,800% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $1.19K | +$755 | +173 | New |
|
|
3
Morgan Stanley
New York
| $713 | -$12.7K | -2,914 | -97% |
|
4
Wells Fargo
San Francisco,
California
| $123 | +$4 | +1 | +6% |
|
|
FDCDDQ
5
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $96 | – | – | – |
|
|
6
Osaic Holdings
Scottsdale,
Arizona
| $34 | +$4 | +1 | +25% |
|
|
AF
7
Allworth Financial
Folsom,
California
| $14 | +$4 | +1 | +100% |
|
|
EWP
8
Elevation Wealth Partners
Santa Rosa,
California
| $7 | – | – | – |
|
|
9
BNP Paribas Financial Markets
Paris,
France
| $7 | +$4 | +1 | New |
|
|
10
Walleye Capital
New York
| – | -$83.1K | -24,216 | Closed |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$3.33K | -969 | Closed |
|
|
TSS
12
Two Sigma Securities
New York
| – | -$2.84K | -861 | Closed |
|
GLMD Hedge Fund Activity: Q3 2024 in Review
10 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2024, worth a combined $38.3K — down 66% from $113K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of GLMD and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, adding an estimated $22.9K. The largest seller was Walleye Capital, exiting entirely with an estimated $83.1K sold.
- 10 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2024, down from 12 in Q2 2024.
- Funds reported $38.3K of Galmed Pharmaceuticals stock for Q3 2024, down 66% quarter-over-quarter.
- 2 funds opened new Galmed Pharmaceuticals positions in Q3 2024 and 3 closed out, a net change of -1 holder.
- The largest Galmed Pharmaceuticals buyer in Q3 2024 was UBS Group, an estimated $22.9K added.
- The largest Galmed Pharmaceuticals seller in Q3 2024 was Walleye Capital, an estimated $83.1K sold.
Based on aggregated 13F filings for Q3 2024.